SCHEMBL32669245

SCHEMBL32669245

CN(C)CCc1c[nH]c2ccc(O)c(F)c12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 11/20 0.67
HTR2A P28223 12/20 0.65
HTR2C P28335 11/20 0.65
HTR2B P41595 10/20 0.65
HTR6 P50406 3/20 0.65
HTR1D P28221 3/20 0.65
HTR1B P28222 3/20 0.65
HTR7 P34969 2/20 0.65
HTR5A P47898 2/20 0.65
DRD1 P21728 1/20 0.65
HTR1E P28566 1/20 0.65
ADORA2A P29274 1/20 0.65
ADORA2B P29275 1/20 0.65
DRD3 P35462 1/20 0.65
MPO P05164 1/20 0.54
SLC6A4 P31645 1/20 0.54
HTR1F P30939 1/20 0.48
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32669315 0.86 HTR1A (0.67) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL26185608 0.85 HTR2A (0.68) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL25437964 0.85 HTR1A (0.70) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL25747588 0.84 HTR2A (0.67) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL31005467 0.84 HTR2A (0.67) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL30681603 0.84 HTR2A (0.67) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL3804978 0.84 HTR2A (0.67) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL8542063 0.82 HTR2A (0.65) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL30916159 0.80 HTR1A (1.00) HTR1AHTR2AHTR2CHTR2BHTR6
SCHEMBL25747526 0.80 HTR1A (1.00) HTR1AHTR2AHTR2CHTR2BHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034119-A1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034119-A1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS HTR4, OPRM1, HTR7 HTR1A 4/4885HTR2A 12/4885HTR2C 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.